Celgene Corporation (CELG) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA) Comparison side by side

Celgene Corporation (NASDAQ:CELG) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Idera Pharmaceuticals Inc. N/A 105.25 62.66M -2.48 0.00 Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 represents Celgene Corporation (NASDAQ:CELG) and Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s return on assets, return on equity and net margins. Net Margins Return on Equity Return on Assets Celgene Corporation 26.51% 56.8% 8.7% Idera Pharmaceuticals Inc. 0.00% -68.4% -60.4% Volatility & Risk

A 1.47 beta means Celgene Corporation’s volatility is 47.00% more than Standard and Poor’s 500’s volatility. Idera Pharmaceuticals Inc. has a 2.22 beta and it is 122.00% more volatile than Standard and Poor’s 500.


2.1 and 2 are the respective Current Ratio and a Quick Ratio of Celgene Corporation. Its rival Idera Pharmaceuticals Inc.’s Current and Quick Ratios are 8.2 and 8.2 respectively. Idera Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Celgene Corporation.

Analyst Recommendations

The following table delivered below contains the ratings and recommendations for Celgene Corporation and Idera Pharmaceuticals Inc.

Celgene Corporation’s downside potential currently stands at -1.09% and an $88.17 average target price. Meanwhile, Idera Pharmaceuticals Inc.’s average target price is $14, while its potential upside is 391.23%. The information presented earlier suggests that Idera Pharmaceuticals Inc. looks more robust than Celgene Corporation as far as analyst opinion.

Insider & Institutional Ownership

Institutional investors owned 76.3% of Celgene Corporation shares and 44.4% of Idera Pharmaceuticals Inc. shares. Insiders owned 0.33% of Celgene Corporation shares. On the other hand, insiders owned about 0.4% of Idera Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Celgene Corporation -4.9% -8.98% -22.96% -12.32% -33.15% -34.19% Idera Pharmaceuticals Inc. -4.51% -28.7% -29.39% -57.51% -57.51% -61.14% For the past year Celgene Corporation’s stock price has smaller decline than Idera Pharmaceuticals Inc.


Celgene Corporation beats on 8 of the 12 factors Idera Pharmaceuticals Inc.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. and Nimbus Therapeutics. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Click Here to Continue...

Add a Comment

Your email address will not be published. Required fields are marked *